Outbreak of sexually transmitted, extensively drug-resistant Shigella sonnei in the UK, 2021-22: a descriptive epidemiological study.


Journal

The Lancet. Infectious diseases
ISSN: 1474-4457
Titre abrégé: Lancet Infect Dis
Pays: United States
ID NLM: 101130150

Informations de publication

Date de publication:
Oct 2022
Historique:
received: 28 03 2022
revised: 19 05 2022
accepted: 19 05 2022
pubmed: 10 7 2022
medline: 28 9 2022
entrez: 9 7 2022
Statut: ppublish

Résumé

Shigellosis, traditionally a foodborne and waterborne infection, causes substantial morbidity globally. It is now a leading cause of sexually transmitted gastroenteritis among gay, bisexual, and other men who have sex with men (MSM). We describe an ongoing outbreak of extensively drug-resistant (XDR) Shigella sonnei in the UK. Routine laboratory surveillance (Second Generation Surveillance System, Gastrointestinal Data Warehouse) identified an exceedance of S sonnei clade 5 in England, first detected in September, 2021. Cases within this clade were subsequently reported from Scotland, Wales, and Northern Ireland. Confirmed cases in this outbreak were defined as individuals diagnosed with S sonnei clade 5 in the UK, with a specimen date between Sept 1, 2021, and Feb 9, 2022, who were genomically confirmed as part of a ten-single nucleotide polymorphism (SNP) linkage cluster. We used whole-genome sequencing with SNP typing to identify genomic clusters and antimicrobial-resistance determinants, analysing cases across the UK. We collected demographic, epidemiological, and clinical data from people infected with S sonnei clade 5 in England using questionnaires (standard and bespoke outbreak questionnaires). We used descriptive summary statistics to characterise cases. 72 cases (70 [97%] male, median age 34 years [IQR 27-39]) belonging to the ten-SNP single linkage cluster of S sonnei clade 5 were identified between Sept 4, 2021, and Feb 9, 2022. Isolates were predominantly XDR, with 66 (92%) of 72 harbouring bla We highlight the rapid dissemination of XDR ESBL-producing S sonnei in sexual networks of MSM. We recommend strengthening shigella testing where clinically indicated, antimicrobial-resistance surveillance, and integrated health promotion messaging among all MSM, including PrEP users, to reduce the burden of shigellosis. National Institute for Health Research Health Protection Research Unit in Gastrointestinal Infections at the University of Liverpool in partnership with the UK Health Security Agency.

Sections du résumé

BACKGROUND
Shigellosis, traditionally a foodborne and waterborne infection, causes substantial morbidity globally. It is now a leading cause of sexually transmitted gastroenteritis among gay, bisexual, and other men who have sex with men (MSM). We describe an ongoing outbreak of extensively drug-resistant (XDR) Shigella sonnei in the UK.
METHODS
Routine laboratory surveillance (Second Generation Surveillance System, Gastrointestinal Data Warehouse) identified an exceedance of S sonnei clade 5 in England, first detected in September, 2021. Cases within this clade were subsequently reported from Scotland, Wales, and Northern Ireland. Confirmed cases in this outbreak were defined as individuals diagnosed with S sonnei clade 5 in the UK, with a specimen date between Sept 1, 2021, and Feb 9, 2022, who were genomically confirmed as part of a ten-single nucleotide polymorphism (SNP) linkage cluster. We used whole-genome sequencing with SNP typing to identify genomic clusters and antimicrobial-resistance determinants, analysing cases across the UK. We collected demographic, epidemiological, and clinical data from people infected with S sonnei clade 5 in England using questionnaires (standard and bespoke outbreak questionnaires). We used descriptive summary statistics to characterise cases.
FINDINGS
72 cases (70 [97%] male, median age 34 years [IQR 27-39]) belonging to the ten-SNP single linkage cluster of S sonnei clade 5 were identified between Sept 4, 2021, and Feb 9, 2022. Isolates were predominantly XDR, with 66 (92%) of 72 harbouring bla
INTERPRETATION
We highlight the rapid dissemination of XDR ESBL-producing S sonnei in sexual networks of MSM. We recommend strengthening shigella testing where clinically indicated, antimicrobial-resistance surveillance, and integrated health promotion messaging among all MSM, including PrEP users, to reduce the burden of shigellosis.
FUNDING
National Institute for Health Research Health Protection Research Unit in Gastrointestinal Infections at the University of Liverpool in partnership with the UK Health Security Agency.

Identifiants

pubmed: 35809593
pii: S1473-3099(22)00370-X
doi: 10.1016/S1473-3099(22)00370-X
pii:
doi:

Substances chimiques

Anti-Bacterial Agents 0
beta-Lactamases EC 3.5.2.6

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1503-1510

Investigateurs

Helen Corkin (H)
Asha Abrahams (A)
Holly LeBlond (H)
Janice Lo (J)
Amelia Holgate (A)
John Saunders (J)
Gunveer Plahe (G)
Amoolya Vusirikala (A)
Freddy Green (F)
Mike King (M)
Rediat Tewolde (R)
Andrew Jajja (A)

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2022 Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests We declare no competing of interests.

Auteurs

Hannah Charles (H)

UK Health Security Agency, London, UK. Electronic address: hannah.charles@ukhsa.gov.uk.

Mateo Prochazka (M)

UK Health Security Agency, London, UK.

Katie Thorley (K)

UK Health Security Agency, London, UK.

Adam Crewdson (A)

UK Health Security Agency, London, UK.

David R Greig (DR)

UK Health Security Agency, London, UK; NIRH Health Protection Research Unit for Gastrointestinal Pathogens, Liverpool, UK.

Claire Jenkins (C)

UK Health Security Agency, London, UK; NIRH Health Protection Research Unit for Gastrointestinal Pathogens, Liverpool, UK.

Anais Painset (A)

UK Health Security Agency, London, UK.

Helen Fifer (H)

UK Health Security Agency, London, UK.

Lynda Browning (L)

Public Health Scotland, Glasgow, UK.

Paul Cabrey (P)

Public Health Agency Northern Ireland, Belfast, UK.

Robert Smith (R)

Public Health Wales, Cardiff, UK.

Daniel Richardson (D)

University Hospitals Sussex NHS Foundation Trust, Brighton, UK; Brighton & Sussex Medical School, Brighton, UK.

Laura Waters (L)

Central and North West London NHS Foundation Trust, London, UK.

Katy Sinka (K)

UK Health Security Agency, London, UK.

Gauri Godbole (G)

UK Health Security Agency, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH